Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 01, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

Vimizim Marketing Application Submitted to ANVISA in Brazil

SAN RAFAEL, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has submitted the Vimizim Marketing Application (MA) to the Agência...
June 06, 2013 10:46 ET | Source: BioMarin Pharmaceutical Inc.

UPDATE: Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Goldman Sachs Global Healthcare Conference

SAN RAFAEL, Calif., June 6, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a...
June 06, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at the Goldman Sachs Global Healthcare Conference

SAN RAFAEL, Calif., June 6, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Joshua Grass, Senior Vice President of Corporate and Business Development at...
June 05, 2013 06:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU

SAN RAFAEL, Calif., June 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has initiated the Phase 3 program for PEG-PAL (PEGylated recombinant...
June 03, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Provides Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors at 2013 American Society of Clinical Oncology Annual Meeting

SAN RAFAEL, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP)...
May 30, 2013 16:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at the Jefferies Global Healthcare Conference

SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Chief Financial Officer at BioMarin, will present a company update...
May 30, 2013 07:05 ET | Source: BioMarin Pharmaceutical Inc.

FDA Accepts Vimizim BLA and Grants Priority Review Designation

SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics...
May 30, 2013 07:00 ET | Source: BioMarin Pharmaceutical Inc.

Vimizim MAA Validated by the EMA

SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization...
May 20, 2013 09:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SAN RAFAEL, Calif., May 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on May 15, 2013, the compensation committee of BioMarin's board of directors...
May 16, 2013 17:49 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at ASCO

SAN RAFAEL, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that data from its ongoing Phase 1/2 trial for BMN-673 for genetically-defined cancers...